Generic placeholder image

Combinatorial Chemistry & High Throughput Screening

Editor-in-Chief

ISSN (Print): 1386-2073
ISSN (Online): 1875-5402

Research Article

ERH Impacts Patient Prognosis and Tumor Immune Microenvironment: A Pan-Cancer Analysis

Author(s): Qianhui Gong, Qiong Li, Zhichao Xu and Xiaobing Shen*

Volume 28, Issue 5, 2025

Published on: 04 April, 2024

Page: [853 - 871] Pages: 19

DOI: 10.2174/0113862073295696240322084341

Price: $65

Abstract

Background: The enhancer of rudimentary homolog (ERH) has been shown to play significant roles in tumorigenesis and progression. However, few systematic pan-cancer analyses about ERH have been described.

Methods: From the tumor immune estimation resource web server2.0 (TIMER2.0), the Genotype- Tissue Expression database (GTEx) and the Gene Expression Profile Interactive Analysis version 2 (GEPIA2) databases, we explored the expression profiles and prognostic significance of ERH in 33 cancers. The Clinical Proteomic Tumor Analysis Consortium (CPTAC) and the Human Protein Atlas (HPA) databases were further used to examine the differential expression of ERH at the protein level. The genetic alteration profile was obtained from the cBioPortal. The correlation between ERH expression and the quantities of immune infiltrating cells was examined by the TIMER tool. Spearman's correlation test was conducted to analyze the association between ERH expression status and a number of prognostic indicators, including immune checkpoints, TMB, MSI, immune neoantigen, MMR genes, and DNA methyltransferases. Protein- Protein Interaction analyses were performed in the String and GeneMANIA databases, and enrichment analysis and predicted signaling pathways were identified through GO and KEGG. To make our results convincing, we validated them in six datasets in the Gene Expression Omnibus (GEO) database. In addition, we verified the expression of ERH between gastric cancer tissues and adjacent normal tissues by RT-qPCR.

Results: ERH expression was elevated in numerous tumors, and it was associated with the patient's prognosis. Furthermore, the quantities of immune infiltrating cells and immune checkpoint genes were remarkably associated with ERH. TMB and MSI were related to ERH expression in 14 and 15 cancer types, respectively. Moreover, the expression of ERH was strongly associated with MMR defects in multiple cancer types, and almost all tumors showed co-expression of ERH and four DNA methyltransferases. The results of GO and KEGG analysis confirmed that ERH potentially impacts several important signaling pathways. Both the GEO datasets and the RTqPCR experiment validated our previous analysis.

Conclusion: Our pan-cancer analysis demonstrated the characterization of ERH in multiple tumors. ERH may be a valuable novel biological indicator for assessing immunotherapy efficacy and prognosis in various malignancies.

Keywords: ERH, pan-cancer analysis, tumor, immune infiltration, prognosis.

Graphical Abstract
[1]
Alves de Lima, E., Jr; Teixeira, A.A.S.; Biondo, L.A.; Diniz, T.A.; Silveira, L.S.; Coletti, D.; Busquets Rius, S.; Rosa Neto, J.C. Exercise reduces the resumption of tumor growth and proteolytic pathways in the skeletal muscle of mice following chemotherapy. Cancers , 2020, 12(11), 3466.
[http://dx.doi.org/10.3390/cancers12113466] [PMID: 33233839]
[2]
Ribas, A.; Wolchok, J.D. Cancer immunotherapy using checkpoint blockade. Science, 2018, 359(6382), 1350-1355.
[http://dx.doi.org/10.1126/science.aar4060] [PMID: 29567705]
[3]
Danesi, R.; Fogli, S.; Indraccolo, S.; Del Re, M.; Dei Tos, A.P.; Leoncini, L.; Antonuzzo, L.; Bonanno, L.; Guarneri, V.; Pierini, A.; Amunni, G.; Conte, P. Druggable targets meet oncogenic drivers: Opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards. ESMO Open, 2021, 6(2), 100040.
[http://dx.doi.org/10.1016/j.esmoop.2020.100040] [PMID: 33540286]
[4]
Hegde, P.S.; Chen, D.S. Top 10 challenges in cancer immunotherapy. Immunity, 2020, 52(1), 17-35.
[http://dx.doi.org/10.1016/j.immuni.2019.12.011] [PMID: 31940268]
[5]
Liu, B.; Fan, Y.; Song, Z.; Han, B.; Meng, Y.; Cao, P.; Tan, K. Identification of DRP1 as a prognostic factor correlated with immune infiltration in breast cancer. Int. Immunopharmacol.,, 2020, 89(Pt B), 107078.
[http://dx.doi.org/10.1016/j.intimp.2020.107078] [PMID: 33049497]
[6]
Ye, W.; Luo, C.; Liu, F.; Liu, Z.; Chen, F. CD96 correlates with immune infiltration and impacts patient prognosis: A pan-cancer analysis. Front. Oncol., 2021, 11, 634617.
[http://dx.doi.org/10.3389/fonc.2021.634617] [PMID: 33680972]
[7]
Li, M.; Zhang, Z.; Guan, L.; Ji, S.; Lu, P. ERH gene knockdown inhibits the proliferation and migration of ARPE-19 cells through MCM complex and EMT process. Gene, 2024, 892, 147855.
[http://dx.doi.org/10.1016/j.gene.2023.147855] [PMID: 37778419]
[8]
Pang, K.; Li, M.; Hao, L.; Shi, Z.; Feng, H.; Chen, B.; Ma, Y.; Xu, H.; Pan, D.; Chen, Z.S.; Han, C. ERH gene and its role in cancer cells. Front. Oncol., 2022, 12, 900496.
[http://dx.doi.org/10.3389/fonc.2022.900496] [PMID: 35677162]
[9]
Jin, T.; Guo, F.; Serebriiskii, I.G.; Howard, A.; Zhang, Y.Z.A. 1.55 Å resolution X‐ray crystal structure of HEF2/ERH and insights into its transcriptional and cell‐cycle interaction networks. Proteins, 2007, 68(2), 427-437.
[http://dx.doi.org/10.1002/prot.21343] [PMID: 17444515]
[10]
Zafrakas, M.; Losen, I.; Knüchel, R.; Dahl, E. Enhancer of the rudimentary gene homologue (ERH) expression pattern in sporadic human breast cancer and normal breast tissue. BMC Cancer, 2008, 8(1), 145.
[http://dx.doi.org/10.1186/1471-2407-8-145] [PMID: 18500978]
[11]
Zhang, D.; Chu, Y.; Song, K.; Chen, Y.; Liu, W.; Lv, T.; Wang, J.; Zhao, H.; Ren, Y.; Xu, J.; Xia, N.; Li, H.; Yao, Q. Knockdown of enhancer of rudimentary homolog inhibits proliferation and metastasis in ovarian cancer by regulating epithelial-mesenchymal transition. Biomed. Pharmacother., 2020, 125, 109974.
[http://dx.doi.org/10.1016/j.biopha.2020.109974] [PMID: 32036222]
[12]
Balic, J.J.; Garama, D.J.; Saad, M.I.; Yu, L.; West, A.C.; West, A.J.; Livis, T.; Bhathal, P.S.; Gough, D.J.; Jenkins, B.J. Serine-phosphorylated STAT3 promotes tumorigenesis via modulation of RNA polymerase transcriptional activity. Cancer Res., 2019, 79(20), 5272-5287.
[http://dx.doi.org/10.1158/0008-5472.CAN-19-0974] [PMID: 31481496]
[13]
Li, Z.; Wang, Q.; Peng, S.; Yao, K.; Chen, J.; Tao, Y.; Gao, Z.; Wang, F.; Li, H.; Cai, W.; Lai, Y.; Li, K.; Chen, X.; Huang, H. The metastatic promoter DEPDC1B induces epithelial‐mesenchymal transition and promotes prostate cancer cell proliferation via Rac1‐PAK1 signaling. Clin. Transl. Med., 2020, 10(6), e191.
[http://dx.doi.org/10.1002/ctm2.191] [PMID: 33135357]
[14]
Zhang, S.; Shi, W.; Hu, W.; Ma, D.; Yan, D.; Yu, K.; Zhang, G.; Cao, Y.; Wu, J.; Jiang, C.; Wang, Z. DEP domain-containing protein 1B (DEPDC1B) promotes migration and invasion in pancreatic cancer through the Rac1/PAK1-LIMK1-Cofilin1 signaling pathway. OncoTargets Ther., 2020, 13, 1481-1496.
[http://dx.doi.org/10.2147/OTT.S229055] [PMID: 32110046]
[15]
Weinstein, J.N.; Collisson, E.A.; Mills, G.B.; Shaw, K.R.M.; Ozenberger, B.A.; Ellrott, K.; Shmulevich, I.; Sander, C.; Stuart, J.M. The cancer genome atlas pan-cancer analysis project. Nat. Genet., 2013, 45(10), 1113-1120.
[http://dx.doi.org/10.1038/ng.2764] [PMID: 24071849]
[16]
Li, T.; Fu, J.; Zeng, Z.; Cohen, D.; Li, J.; Chen, Q.; Li, B.; Liu, X.S. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res., 2020, 48(W1), W509-W514.
[http://dx.doi.org/10.1093/nar/gkaa407] [PMID: 32442275]
[17]
Lonsdale, J.; Thomas, J.; Salvatore, M.; Phillips, R.; Lo, E.; Shad, S.; Hasz, R.; Walters, G.; Garcia, F.; Young, N.; Foster, B.; Moser, M.; Karasik, E.; Gillard, B.; Ramsey, K.; Sullivan, S.; Bridge, J.; Magazine, H.; Syron, J.; Fleming, J.; Siminoff, L.; Traino, H.; Mosavel, M.; Barker, L.; Jewell, S.; Rohrer, D.; Maxim, D.; Filkins, D.; Harbach, P.; Cortadillo, E.; Berghuis, B.; Turner, L.; Hudson, E.; Feenstra, K.; Sobin, L.; Robb, J.; Branton, P.; Korzeniewski, G.; Shive, C.; Tabor, D.; Qi, L.; Groch, K.; Nampally, S.; Buia, S.; Zimmerman, A.; Smith, A.; Burges, R.; Robinson, K.; Valentino, K.; Bradbury, D.; Cosentino, M.; Diaz-Mayoral, N.; Kennedy, M.; Engel, T.; Williams, P.; Erickson, K.; Ardlie, K.; Winckler, W.; Getz, G.; DeLuca, D.; MacArthur, D.; Kellis, M.; Thomson, A.; Young, T.; Gelfand, E.; Donovan, M.; Meng, Y.; Grant, G.; Mash, D.; Marcus, Y.; Basile, M.; Liu, J.; Zhu, J.; Tu, Z.; Cox, N.J.; Nicolae, D.L.; Gamazon, E.R. Im, H.K.; Konkashbaev, A.; Pritchard, J.; Stevens, M.; Flutre, T.; Wen, X.; Dermitzakis, E.T.; Lappalainen, T.; Guigo, R.; Monlong, J.; Sammeth, M.; Koller, D.; Battle, A.; Mostafavi, S.; McCarthy, M.; Rivas, M.; Maller, J.; Rusyn, I.; Nobel, A.; Wright, F.; Shabalin, A.; Feolo, M.; Sharopova, N.; Sturcke, A.; Paschal, J.; Anderson, J.M.; Wilder, E.L.; Derr, L.K.; Green, E.D.; Struewing, J.P.; Temple, G.; Volpi, S.; Boyer, J.T.; Thomson, E.J.; Guyer, M.S.; Ng, C.; Abdallah, A.; Colantuoni, D.; Insel, T.R.; Koester, S.E.; Little, A.R.; Bender, P.K.; Lehner, T.; Yao, Y.; Compton, C.C.; Vaught, J.B.; Sawyer, S.; Lockhart, N.C.; Demchok, J.; Moore, H.F. The genotype-tissue expression (GTEx) project. Nat. Genet., 2013, 45(6), 580-585.
[http://dx.doi.org/10.1038/ng.2653] [PMID: 23715323]
[18]
Tang, Z.; Kang, B.; Li, C.; Chen, T.; Zhang, Z. GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res., 2019, 47(W1), W556-W560.
[http://dx.doi.org/10.1093/nar/gkz430] [PMID: 31114875]
[19]
Cui, X.; Zhang, X.; Liu, M.; Zhao, C.; Zhang, N.; Ren, Y.; Su, C.; Zhang, W.; Sun, X.; He, J.; Gao, X.; Yang, J. A pan-cancer analysis of the oncogenic role of staphylococcal nuclease domain-containing protein 1 (SND1) in human tumors. Genomics, 2020, 112(6), 3958-3967.
[http://dx.doi.org/10.1016/j.ygeno.2020.06.044] [PMID: 32645525]
[20]
Yang, H.; Adam, R.C.; Ge, Y.; Hua, Z.L.; Fuchs, E. Epithelial-mesenchymal micro-niches govern stem cell lineage choices. Cell, 2017, 169(3), 483-496.e13.
[http://dx.doi.org/10.1016/j.cell.2017.03.038] [PMID: 28413068]
[21]
Alam, M.S.; Sultana, A.; Sun, H.; Wu, J.; Guo, F.; Li, Q.; Ren, H.; Hao, Z.; Zhang, Y.; Wang, G. Bioinformatics and network-based screening and discovery of potential molecular targets and small molecular drugs for breast cancer. Front. Pharmacol., 2022, 13, 942126.
[http://dx.doi.org/10.3389/fphar.2022.942126] [PMID: 36204232]
[22]
Tsai, W.L.; Wang, C.Y.; Lee, Y.C.; Tang, W.C.; Anuraga, G.; Ta, H.D.K.; Wu, Y.F.; Lee, K.H. A new light on potential therapeutic targets for colorectal cancer treatment. Biomedicines, 2021, 9(10), 1438.
[http://dx.doi.org/10.3390/biomedicines9101438] [PMID: 34680556]
[23]
Zhang, C.; Li, Y.; Qian, J.; Zhu, Z.; Huang, C.; He, Z.; Zhou, L.; Gong, Y. Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy. Front. Immunol., 2022, 13, 1020729.
[http://dx.doi.org/10.3389/fimmu.2022.1020729] [PMID: 36479115]
[24]
Shi, Y.; Wang, Y.; Zhang, W.; Niu, K.; Mao, X.; Feng, K.; Zhang, Y. N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment. Front. Endocrinol., 2023, 14, 1153802.
[http://dx.doi.org/10.3389/fendo.2023.1153802] [PMID: 37469973]
[25]
Mo, G.; Long, X.; Cao, L.; Tang, Y.; Yan, Y.; Guo, T. A six-gene prognostic model based on neutrophil extracellular traps (NETs)-related gene signature for lung adenocarcinoma. Comb. Chem. High Throughput Screen., 2024, 27.
[http://dx.doi.org/10.2174/0113862073282003240119064337] [PMID: 38357943]
[26]
Xie, R.; Liu, L.; Lu, X.; He, C.; Li, G. Identification of the diagnostic genes and immune cell infiltration characteristics of gastric cancer using bioinformatics analysis and machine learning. Front. Genet., 2023, 13, 1067524.
[http://dx.doi.org/10.3389/fgene.2022.1067524] [PMID: 36685898]
[27]
Chandrashekar, D.S.; Bashel, B.; Balasubramanya, S.A.H.; Creighton, C.J.; Ponce-Rodriguez, I.; Chakravarthi, B.V.S.K.; Varambally, S. UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia, 2017, 19(8), 649-658.
[http://dx.doi.org/10.1016/j.neo.2017.05.002] [PMID: 28732212]
[28]
Uhlen, M.; Oksvold, P.; Fagerberg, L.; Lundberg, E.; Jonasson, K.; Forsberg, M.; Zwahlen, M.; Kampf, C.; Wester, K.; Hober, S.; Wernerus, H.; Björling, L.; Ponten, F. Towards a knowledge-based human protein atlas. Nat. Biotechnol., 2010, 28(12), 1248-1250.
[http://dx.doi.org/10.1038/nbt1210-1248] [PMID: 21139605]
[29]
Cerami, E.; Gao, J.; Dogrusoz, U.; Gross, B.E.; Sumer, S.O.; Aksoy, B.A.; Jacobsen, A.; Byrne, C.J.; Heuer, M.L.; Larsson, E.; Antipin, Y.; Reva, B.; Goldberg, A.P.; Sander, C.; Schultz, N. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov., 2012, 2(5), 401-404.
[http://dx.doi.org/10.1158/2159-8290.CD-12-0095] [PMID: 22588877]
[30]
Shi, K.; Zhou, J.; Li, M.; Yan, W.; Zhang, J.; Zhang, X.; Jiang, L. Pan-cancer analysis of PLAU indicates its potential prognostic value and correlation with neutrophil infiltration in BLCA. Biochim. Biophys. Acta Mol. Basis Dis., 2024, 1870(2), 166965.
[http://dx.doi.org/10.1016/j.bbadis.2023.166965] [PMID: 38000776]
[31]
Baretti, M.; Le, D.T. DNA mismatch repair in cancer. Pharmacol. Ther., 2018, 189, 45-62.
[http://dx.doi.org/10.1016/j.pharmthera.2018.04.004] [PMID: 29669262]
[32]
Peng, L.; Li, J.; Wu, J.; Xu, B.; Wang, Z.; Giamas, G.; Stebbing, J.; Yu, Z. A pan-cancer analysis of SMARCA4 alterations in human cancers. Front. Immunol., 2021, 12, 762598.
[http://dx.doi.org/10.3389/fimmu.2021.762598] [PMID: 34675941]
[33]
Bagchi, A.; Banerjee, A.; Chakrabortty, S. Rindler physics on the string worldsheet. Phys. Rev. Lett., 2021, 126(3), 031601.
[http://dx.doi.org/10.1103/PhysRevLett.126.031601] [PMID: 33543967]
[34]
Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N.S.; Wang, J.T.; Ramage, D.; Amin, N.; Schwikowski, B.; Ideker, T. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res., 2003, 13(11), 2498-2504.
[http://dx.doi.org/10.1101/gr.1239303] [PMID: 14597658]
[35]
Warde-Farley, D.; Donaldson, S.L.; Comes, O.; Zuberi, K.; Badrawi, R.; Chao, P.; Franz, M.; Grouios, C.; Kazi, F.; Lopes, C.T.; Maitland, A.; Mostafavi, S.; Montojo, J.; Shao, Q.; Wright, G.; Bader, G.D.; Morris, Q. The GeneMANIA prediction server: Biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res.,, 2010, 38(Web Server issue)(Suppl. 2), W214-W220.
[http://dx.doi.org/10.1093/nar/gkq537] [PMID: 20576703]
[36]
Zhou, Y.; Zhou, B.; Pache, L.; Chang, M.; Khodabakhshi, A.H.; Tanaseichuk, O.; Benner, C.; Chanda, S.K. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun., 2019, 10(1), 1523.
[http://dx.doi.org/10.1038/s41467-019-09234-6] [PMID: 30944313]
[37]
Sherman, B.T.; Hao, M.; Qiu, J.; Jiao, X.; Baseler, M.W.; Lane, H.C.; Imamichi, T.; Chang, W. DAVID: A web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res., 2022, 50(W1), W216-W221.
[http://dx.doi.org/10.1093/nar/gkac194] [PMID: 35325185]
[38]
Liu, J.; Chen, Z.; Zhao, P.; Li, W. Prognostic and immune regulating roles of YIF1B in pan-cancer: A potential target for both survival and therapy response evaluation. Biosci. Rep., 2020, 40(7), BSR20201384.
[http://dx.doi.org/10.1042/BSR20201384] [PMID: 32648580]
[39]
Chen, Z.Y.; Hsieh, Y.M.; Huang, C.C.; Tsai, C.C. Inhibitory effects of probiotic lactobacillus on the growth of human colonic carcinoma cell line HT-29. Molecules, 2017, 22(1), 107.
[http://dx.doi.org/10.3390/molecules22010107] [PMID: 28075415]
[40]
Xiao, M.; Tang, N.; Yan, Y.; Li, Z.; Shi, S.; He, S.; Chen, Z.; Cao, K.; Chen, J.; Zhou, J.; Chen, X. Knockdown of enhancer of rudimentary homolog expression attenuates proliferation, cell cycle and apoptosis of melanoma cells. Melanoma Res., 2021, 31(4), 309-318.
[http://dx.doi.org/10.1097/CMR.0000000000000747] [PMID: 34193803]
[41]
Pang, K.; Zhang, Z.; Hao, L.; Shi, Z.; Chen, B.; Zang, G.; Dong, Y.; Li, R.; Liu, Y.; Wang, J.; Zhang, J.; Cai, L.; Han, X.; Han, C. The ERH gene regulates migration and invasion in 5637 and T24 bladder cancer cells. BMC Cancer, 2019, 19(1), 225.
[http://dx.doi.org/10.1186/s12885-019-5423-9] [PMID: 30866868]
[42]
Park, J.H.; Park, M.; Park, S.Y.; Lee, Y.J.; Hong, S.C.; Jung, E.J.; Ju, Y.T.; Jeong, C.Y.; Kim, J.Y.; Ko, G.H.; Hah, Y.S.; Jeong, S.H. ERH overexpression is associated with decreased cell migration and invasion and a good prognosis in gastric cancer. Transl. Cancer Res., 2020, 9(9), 5281-5291.
[http://dx.doi.org/10.21037/tcr-20-1498] [PMID: 35117894]
[43]
Zhang, Y.; Chen, W.; Cheng, X.; Wang, F.; Gao, C.; Song, F.; Song, F.; Liang, X.; Fang, W.; Chen, Z. Sphingomyelin phodiesterase acid-like 3A promotes hepatocellular carcinoma growth through the enhancer of rudimentary homolog. Front. Oncol., 2022, 12, 852765.
[http://dx.doi.org/10.3389/fonc.2022.852765] [PMID: 35686107]
[44]
Weng, M.T.; Tung, T.H.; Lee, J.H.; Wei, S.C.; Lin, H.L.; Huang, Y.J.; Wong, J.M.; Luo, J.; Sheu, J.C. Enhancer of rudimentary homolog regulates DNA damage response in hepatocellular carcinoma. Sci. Rep., 2015, 5(1), 9357.
[http://dx.doi.org/10.1038/srep09357] [PMID: 25880358]
[45]
Weng, M.T.; Lee, J.H.; Wei, S.C.; Li, Q.; Shahamatdar, S.; Hsu, D.; Schetter, A.J.; Swatkoski, S.; Mannan, P.; Garfield, S.; Gucek, M.; Kim, M.K.H.; Annunziata, C.M.; Creighton, C.J.; Emanuele, M.J.; Harris, C.C.; Sheu, J.C.; Giaccone, G.; Luo, J. Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. Proc. Natl. Acad. Sci. USA, 2012, 109(52), E3659-E3667.
[http://dx.doi.org/10.1073/pnas.1207673110] [PMID: 23236152]
[46]
Leclerc, J.; Flament, C.; Lovecchio, T.; Delattre, L.; Ait Yahya, E.; Baert-Desurmont, S.; Burnichon, N.; Bronner, M.; Cabaret, O.; Lejeune, S.; Guimbaud, R.; Morin, G.; Mauillon, J.; Jonveaux, P.; Laurent-Puig, P.; Frébourg, T.; Porchet, N.; Buisine, M.P. Diversity of genetic events associated with MLH1 promoter methylation in Lynch syndrome families with heritable constitutional epimutation. Genet. Med., 2018, 20(12), 1589-1599.
[http://dx.doi.org/10.1038/gim.2018.47] [PMID: 29790873]
[47]
Lei, X.; Lei, Y.; Li, J.K.; Du, W.X.; Li, R.G.; Yang, J.; Li, J.; Li, F.; Tan, H.B. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. Cancer Lett., 2020, 470, 126-133.
[http://dx.doi.org/10.1016/j.canlet.2019.11.009] [PMID: 31730903]
[48]
Weng, M.T.; Luo, J. The enigmatic ERH protein: Its role in cell cycle, RNA splicing and cancer. Protein Cell, 2013, 4(11), 807-812.
[http://dx.doi.org/10.1007/s13238-013-3056-3] [PMID: 24078386]
[49]
Liu, J.N.; Kong, X.S.; Huang, T.; Wang, R.; Li, W.; Chen, Q.F. Clinical implications of aberrant PD-1 and CTLA4 expression for cancer immunity and prognosis: A pan-cancer study. Front. Immunol., 2020, 11, 2048.
[http://dx.doi.org/10.3389/fimmu.2020.02048] [PMID: 33072070]
[50]
Huo, J.; Wu, L.; Zang, Y.; Dong, H.; Liu, X.; He, F.; Zhang, X. Eight-gene metabolic signature related with tumor-associated macrophages predicting overall survival for hepatocellular carcinoma. BMC Cancer, 2021, 21(1), 31.
[http://dx.doi.org/10.1186/s12885-020-07734-z] [PMID: 33413205]
[51]
Wu, Z.H.; Tang, Y.; Yu, H.; Li, H.D. The role of ferroptosis in breast cancer patients: A comprehensive analysis. Cell Death Discov., 2021, 7(1), 93.
[http://dx.doi.org/10.1038/s41420-021-00473-5] [PMID: 33947836]
[52]
Yang, J.; Liao, X.; Agarwal, M.K.; Barnes, L.; Auron, P.E.; Stark, G.R. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFκB. Genes Dev., 2007, 21(11), 1396-1408.
[http://dx.doi.org/10.1101/gad.1553707] [PMID: 17510282]
[53]
Köberlin, M.S.; Snijder, B.; Heinz, L.X.; Baumann, C.L.; Fauster, A.; Vladimer, G.I.; Gavin, A.C.; Superti-Furga, G. A conserved circular network of coregulated lipids modulates innate immune responses. Cell, 2015, 162(1), 170-183.
[http://dx.doi.org/10.1016/j.cell.2015.05.051] [PMID: 26095250]
[54]
Steuer, C.E.; Ramalingam, S.S. Tumor mutation burden: Leading immunotherapy to the era of precision medicine? J. Clin. Oncol., 2018, 36(7), 631-632.
[http://dx.doi.org/10.1200/JCO.2017.76.8770] [PMID: 29337637]
[55]
Zhang, C.; Zhang, M.; Ge, S.; Huang, W.; Lin, X.; Gao, J.; Gong, J.; Shen, L. Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K‐Akt signaling in gastric cancer. Cancer Med., 2019, 8(10), 4766-4781.
[http://dx.doi.org/10.1002/cam4.2360] [PMID: 31243897]
[56]
Tang, J.; Pearce, L.; O’Donnell-Tormey, J.; Hubbard-Lucey, V.M. Erratum: Trends in the global immuno-oncology landscape. Nat. Rev. Drug Discov., 2018, 17(12), 922.
[http://dx.doi.org/10.1038/nrd.2018.202] [PMID: 30361553]
[57]
Lee, D.W.; Han, S.W.; Bae, J.M.; Jang, H.; Han, H.; Kim, H.; Bang, D.; Jeong, S.Y.; Park, K.J.; Kang, G.H.; Kim, T.Y. Tumor mutation burden and prognosis in patients with colorectal cancer treated with adjuvant fluoropyrimidine and oxaliplatin. Clin. Cancer Res., 2019, 25(20), 6141-6147.
[http://dx.doi.org/10.1158/1078-0432.CCR-19-1105] [PMID: 31285374]
[58]
Devarakonda, S.; Rotolo, F.; Tsao, M.S.; Lanc, I.; Brambilla, E.; Masood, A.; Olaussen, K.A.; Fulton, R.; Sakashita, S.; McLeer-Florin, A.; Ding, K.; Le Teuff, G.; Shepherd, F.A.; Pignon, J.P.; Graziano, S.L.; Kratzke, R.; Soria, J.C.; Seymour, L.; Govindan, R.; Michiels, S. Tumor mutation burden as a biomarker in resected non–small-cell lung cancer. J. Clin. Oncol., 2018, 36(30), 2995-3006.
[http://dx.doi.org/10.1200/JCO.2018.78.1963] [PMID: 30106638]
[59]
Gryfe, R.; Kim, H.; Hsieh, E.T.K.; Aronson, M.D.; Holowaty, E.J.; Bull, S.B.; Redston, M.; Gallinger, S. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N. Engl. J. Med., 2000, 342(2), 69-77.
[http://dx.doi.org/10.1056/NEJM200001133420201] [PMID: 10631274]
[60]
Overman, M.J.; McDermott, R.; Leach, J.L.; Lonardi, S.; Lenz, H.J.; Morse, M.A.; Desai, J.; Hill, A.; Axelson, M.; Moss, R.A.; Goldberg, M.V.; Cao, Z.A.; Ledeine, J.M.; Maglinte, G.A.; Kopetz, S.; André, T. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study. Lancet Oncol., 2017, 18(9), 1182-1191.
[http://dx.doi.org/10.1016/S1470-2045(17)30422-9] [PMID: 28734759]
[61]
Mariathasan, S.; Turley, S.J.; Nickles, D.; Castiglioni, A.; Yuen, K.; Wang, Y.; Kadel, E.E., III; Koeppen, H.; Astarita, J.L.; Cubas, R.; Jhunjhunwala, S.; Banchereau, R.; Yang, Y.; Guan, Y.; Chalouni, C.; Ziai, J.; Şenbabaoğlu, Y.; Santoro, S.; Sheinson, D.; Hung, J.; Giltnane, J.M.; Pierce, A.A.; Mesh, K.; Lianoglou, S.; Riegler, J.; Carano, R.A.D.; Eriksson, P.; Höglund, M.; Somarriba, L.; Halligan, D.L.; van der Heijden, M.S.; Loriot, Y.; Rosenberg, J.E.; Fong, L.; Mellman, I.; Chen, D.S.; Green, M.; Derleth, C.; Fine, G.D.; Hegde, P.S.; Bourgon, R.; Powles, T. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature, 2018, 554(7693), 544-548.
[http://dx.doi.org/10.1038/nature25501] [PMID: 29443960]
[62]
Kwon, M.; Hong, J.Y.; Kim, S.T.; Kim, K.M.; Lee, J. Association of serine/threonine kinase 11 mutations and response to programmed cell death 1 inhibitors in metastatic gastric cancer. Pathol. Res. Pract., 2020, 216(6), 152947.
[http://dx.doi.org/10.1016/j.prp.2020.152947] [PMID: 32284250]
[63]
Lagos, G.G.; Izar, B.; Rizvi, N.A. Beyond tumor PD-L1: Emerging genomic biomarkers for checkpoint inhibitor immunotherapy. Am. Soc. Clin. Oncol. Educ. Book, 2020, 40(40), e47-e57.
[http://dx.doi.org/10.1200/EDBK_289967] [PMID: 32315237]
[64]
Shim, J.H.; Kim, H.S.; Cha, H.; Kim, S.; Kim, T.M.; Anagnostou, V.; Choi, Y.L.; Jung, H.A.; Sun, J.M.; Ahn, J.S.; Ahn, M.J.; Park, K.; Park, W.Y.; Lee, S.H. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients. Ann. Oncol., 2020, 31(7), 902-911.
[http://dx.doi.org/10.1016/j.annonc.2020.04.004] [PMID: 32320754]
[65]
Yoshino, T.; Pentheroudakis, G.; Mishima, S.; Overman, M.J.; Yeh, K.H.; Baba, E.; Naito, Y.; Calvo, F.; Saxena, A.; Chen, L.T.; Takeda, M.; Cervantes, A.; Taniguchi, H.; Yoshida, K.; Kodera, Y.; Kitagawa, Y.; Tabernero, J.; Burris, H.; Douillard, J.Y. JSCO—ESMO—ASCO—JSMO—TOS: International expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Ann. Oncol., 2020, 31(7), 861-872.
[http://dx.doi.org/10.1016/j.annonc.2020.03.299] [PMID: 32272210]
[66]
Kjeldsen, E.; Nielsen, C.J.F.; Roy, A.; Tesauro, C.; Jakobsen, A.K.; Stougaard, M.; Knudsen, B.R. Characterization of camptothecin-induced genomic changes in the camptothecin-resistant T-ALL-derived cell line CPT-K5. Cancer Genomics Proteomics, 2018, 15(2), 91-114.
[PMID: 29496689]
[67]
Huang, S.C.; Ng, K.F.; Chang, I.Y.F.; Chang, C.J.; Chao, Y.C.; Chang, S.C.; Chen, M.C.; Yeh, T.S.; Chen, T.C. The clinicopathological significance of SWI/SNF alterations in gastric cancer is associated with the molecular subtypes. PLoS One, 2021, 16(1), e0245356.
[http://dx.doi.org/10.1371/journal.pone.0245356] [PMID: 33481850]
[68]
Pellat, A.; Netter, J.; Perkins, G.; Cohen, R.; Coulet, F.; Parc, Y.; Svrcek, M.; Duval, A.; André, T. Lynch syndrome: What’s new? Bull. Cancer, 2019, 106(7-8), 647-655.
[http://dx.doi.org/10.1016/j.bulcan.2018.10.009] [PMID: 30527816]
[69]
Mehdi, A.; Rabbani, S.A. Role of methylation in pro- and anti-cancer immunity. Cancers , 2021, 13(3), 545.
[http://dx.doi.org/10.3390/cancers13030545] [PMID: 33535484]
[70]
Daniel, F.I.; Cherubini, K.; Yurgel, L.S.; de Figueiredo, M.A.Z.; Salum, F.G. The role of epigenetic transcription repression and DNA methyltransferases in cancer. Cancer, 2011, 117(4), 677-687.
[http://dx.doi.org/10.1002/cncr.25482] [PMID: 20945317]
[71]
Liu, J.; Wang, Y.; Yin, J.; Yang, Y.; Geng, R.; Zhong, Z.; Ni, S.; Liu, W.; Du, M.; Yu, H.; Bai, J. Pan-cancer analysis revealed SRSF9 as a new biomarker for prognosis and immunotherapy. J. Oncol., 2022, 2022, 1-21.
[http://dx.doi.org/10.1155/2022/3477148] [PMID: 35069733]
[72]
Jiricny, J. The multifaceted mismatch-repair system. Nat. Rev. Mol. Cell Biol., 2006, 7(5), 335-346.
[http://dx.doi.org/10.1038/nrm1907] [PMID: 16612326]
[73]
Geng, Y.; Guan, R.; Hong, W.; Huang, B.; Liu, P.; Guo, X.; Hu, S.; Yu, M.; Hou, B. Identification of m6A-related genes and m6A RNA methylation regulators in pancreatic cancer and their association with survival. Ann. Transl. Med., 2020, 8(6), 387.
[http://dx.doi.org/10.21037/atm.2020.03.98] [PMID: 32355831]

Rights & Permissions Print Cite
© 2026 Bentham Science Publishers | Privacy Policy